Eric Joseph analyst CITI

Currently out of the existing stock ratings of Eric Joseph, 166 are a BUY (64.59%), 73 are a HOLD (28.4%), 18 are a SELL (7%).

Eric Joseph

Work Performance Price Targets & Ratings Chart

Analyst Eric Joseph, currently employed at CITI, has had 50.65% of price targets met with an average potential upside of 41.97%, reached in 190 days on average. Previously, Eric Joseph worked at JPMORGAN.

Eric Joseph has documented 496 price targets and ratings displayed on 56 stocks. The coverage is on Healthcare, Basic Materials, Technology sectors.

Most recent stock forecast was given on ARWR, Arrowhead Pharmaceuticals.

Wall Street Analyst Eric Joseph

Analyst best performing recommendations are on WVE (WAVE LIFE SCIENCES LTD).
The best stock recommendation documented was for VERV (VERVE THERAPEUTICS) on 7/12/2021. The price target of $50 was fulfilled within 1 day with a profit of $1.8 (3.73%), with a performance score of 37.34.

Average potential price target upside

AKBA Akebia Ther ALGS Aligos Therapeutics AUTL Autolus Therapeutics Ltd AVIR Atea Pharmaceuticals BDTX Black Diamond Therapeutics BEAM Beam Therapeutics ENTA Enanta Pharmaceuticals FPRX Five Prime Therapeutics KPTI Karyopharm Therapeutics MNTA Momenta Pharmaceuticals MYOV Myovant Sciences Ltd NRIX Nurix Therapeutics NVAX Novavax OBSV ObsEva SA PTCT PTC Therapeutics RLAY Relay Therapeutics RCKT Rocket Pharmaceuticals HGEN Humanigen IRWD Ironwood Pharmaceuticals TERN Terns Pharmaceuticals XLRN Acceleron Pharma CCCC C4 Therapeutics FRLN Freeline Therapeutics Holdings Plc IGMS IGM Biosciences PLRX Pliant Therapeutics RVMD Revolution Medicines BMEA Biomea Fusion KYMR Kymera Therapeutics MRTX Mirati Ther GLUE Monte Rosa Therapeutics TGTX TG Therapeutics VIR Vir Biotechnology AKRO Akero Therapeutics IPSC Century Therapeutics BLUE Bluebird bio VERV Verve Therapeutics WVE Wave Life Sciences Ltd HLVX Hillevax PRME Prime Medicine CAMP CalAmp Corp URGN UroGen Pharma Ltd ALNY Alnylam Pharmaceuticals BBIO BridgeBio Pharma BMRN Biomarin Pharmaceutical IONS Ionis Pharmaceuticals SEPN Septerna ARWR Arrowhead Pharmaceuticals ASND Ascendis Pharma AS MDGL Madrigal Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 26-Sep-2023

$4.5

$3.47 (336.89%)

$7.5

2 months 14 days ago
(07-Sep-2026)

15/36 (41.67%)

$3.47 (336.89%)

342

Buy Since 03-Jun-2025

$6

$4.97 (482.52%)

$6

4 months 21 days ago
(30-Jun-2026)

0/5 (0%)

$4.79 (395.87%)

Buy Since 28-Nov-2023

$4

$2.97 (288.35%)

$4

7 months 15 days ago
(06-Apr-2026)

3/7 (42.86%)

$2.62 (189.86%)

578

Buy Since 29-Mar-2022

$4

$2.97 (288.35%)

$2

9 months 16 days ago
(05-Feb-2026)

1/2 (50%)

$2.61 (187.77%)

722

Hold Since 31-May-2023

$4

3 years 5 months 22 days ago
(31-May-2023)

1/12 (8.33%)

$2.96 (284.62%)

784

Show more analysts

Stocks Eric Joseph covered previously. Scores are shown for active stocks only.

DTIL Precision BioSciences FR First Industrial Realty Trust LTHM Livent Corp OMER Omeros OPK Opko Health RXRX Recursion Pharmaceuticals

Please expand the browser size to see the chart

Which stock is Eric Joseph most bullish on?

Potential upside of $380.9 has been obtained for MDGL (MADRIGAL PHARMACEUTICALS)

Which stock is Eric Joseph most reserved on?

Potential downside of $14.97 has been obtained for BBIO (BRIDGEBIO PHARMA)

What Year was the first public recommendation made by Eric Joseph?

On 2014
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?